Table 2. Univariate and multivariate analysis for clinicopathological factors associated with brain metastasis in EGFR-mutant patients.
| Covariate† | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Age (<60/≥60) | 2.74 (1.69–4.43) | <0.001* | 2.74 (1.67–4.49) | <0.001* | |
| Gender (Male/female) | 1.26 (0.78–2.03) | 0.331 | |||
| ECOG PS (≥2/0–1) | 1.44 (0.72–2.86) | 0.295 | |||
| Smoking (current-former/never) | 1.20 (0.67–2.15) | 0.522 | |||
| Histology (Non-ADC/ADC) | 2.37 (0.87–6.42) | 0.089 | 1.99 (0.69–5.70) | 0.199 | |
| Stage at diagnosis (M1/M0) | 1.91 (1.05–3.45) | 0.032* | 1.83 (0.98–3.41) | 0.058 | |
| No. metastatic site (≥3/<3) | 1.69 (0.99–2.87) | 0.050* | 1.65 (0.95–2.87) | 0.075 | |
| EGFR subtype (Del19/L858R) | 1.18 (0.73–1.90) | 0.493 | |||
| EGFR subtypes (others/common) | 2.22 (0.96–5.13) | 0.060 | 1.95 (0.80–4.73) | 0.137 | |
†, Category after the slash (/) was set as reference category. *, P<0.05. EGFR, epidermal growth factor receptor; ADC, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; M1, metastatic disease; M0, recurrent disease; OR, odds ratio.